Re: Report Of Exempt Distribution.

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

fuzzyjr

Rank: Vice President [?]

Points: 4892 [?]

Votes: 36 Score: 3.1 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Report Of Exempt Distribution.

in response to

Re: Report Of Exempt Distribution.

KOO-KOO2

posted on Apr 18, 2024 09:20AM

"I'm still betting that Resverlogix will survive. My glass is still half full for RVX"

Just a reminder, the same guy that's had zero success in 20+ years @ rvx is the same guy thats been ruining zenith for 10+ years with zero success.

3 Recommendations

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Please to post a reply